Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
Bristol Myers wins FDA accelerated approval for Zenbexus, the first CELMoD therapy, as data show it doubles MRD-negative complete response rates.
Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn’t always competing head-to-head; it is knowing when to join forces. While both companies reported their first-quarter 2026 earnings earlier this year, their recent double dose of clinical and regulatory breakthroughs across […]
Price target commentary for Merck has shifted toward a US$140 to US$155 range, anchored by a modest uplift in fair value from US$132.78 to US$136.85. Analysts link these higher targets to research that highlights Merck’s pipeline progress, recent business development moves and continued focus on late stage therapeutics. As you read on, you will see how to track these moving pieces and what they could mean for the evolving Merck story in the coming years. Stay updated as the Fair Value for...
Merck stock has almost doubled investors' money over the past five years, yet there is a clear split between valuation tools. A Discounted Cash Flow (DCF) estimate points to a sizeable gap to intrinsic value, while market based multiples suggest the shares are already pricing in a lot of optimism. Merck has returned 99.7% over five years, which puts recent gains in focus as investors weigh how much future growth is already reflected in the price. Ongoing investment in oncology and new...
MRK's Keytruda remains a key growth engine in 2026, but patent loss and rising competition could challenge its long-term sales momentum.
Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%.
Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product launches. Management credited higher demand for KEYTRUDA in both early-stage and metastatic cancers and robust performance in Animal Health as core drivers. CFO Caroline Litchfield highlighted, “Our strong commercial and operational execution continues to drive near-term performance while we invest in our outstanding pipeline.” While market re
Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t
Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.
RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math on who can actually write the check gets complicated fast.
With CPI dropping at 8:30 AM and the Strait of Hormuz near shutdown, Wall Street faces a pivotal morning that could swing stocks sharply in either direction, and analysts at Deutsche Bank, Oppenheimer, Berenberg, and others are already repositioning ahead of the numbers.
Infinimmune is targeting first-in-human studies with its longer-lasting monoclonal antibodies in 2027.
Merck (NYSE:MRK) said the FDA and EMA have accepted supplemental applications to expand ENFLONSIA for preventing RSV in young children at elevated risk. The filings seek to broaden ENFLONSIA's indication in vulnerable pediatric groups where preventative options for RSV are limited. The dual U.S. and European regulatory milestones highlight Merck's efforts to build out its portfolio beyond oncology as attention on the future of Keytruda intensifies. For investors tracking how large drug...
Oncology and animal health drove $16.6B revenue growth amid upcoming patent expirations.
Eli Lilly just posted its fourth straight earnings beat and raised guidance again, but the real question is whether a next-generation obesity drug still sitting below Wall Street's radar could push the stock well past current targets.
Merck's strong Keytruda sales and pipeline progress support its long-term outlook, but falling estimates and patent risks cloud the near term.
Immunocore's 3-month gain reflects Kimmtrak growth and pipeline progress, but valuation and mixed signals temper the momentum case.
Immunocore's Q2 revenue beat reflects strong Kimmtrak demand, but an EPS miss and distributor stocking headwind cloud the near-term outlook.
Bristol Myers Squibb's Growth Portfolio and pipeline support momentum, but generic headwinds and recent gains call for a cautious stance.
